CAJ | 학술논문

卵巢癌死亡率在女性所有肿瘤死亡率中居第5位，妇科肿瘤中居首位。与乳腺癌不同，卵巢癌早期缺乏明显症状和有效筛查，生存率低。目前，美国食品药品管理局（ FDA）只批准了少数卵巢癌的肿瘤标志物检测项目。卵巢癌的肿瘤标志物在疾病诊断、疗效监测和预后判断中被广泛应用。文章综述了现有卵巢癌的肿瘤标志物及其临床应用。
란소암사망솔재녀성소유종류사망솔중거제5위，부과종류중거수위。여유선암불동，란소암조기결핍명현증상화유효사사，생존솔저。목전，미국식품약품관리국（ FDA）지비준료소수란소암적종류표지물검측항목。란소암적종류표지물재질병진단、료효감측화예후판단중피엄범응용。문장종술료현유란소암적종류표지물급기림상응용。
Ovarian cancer is the fifth cause of cancer death in women, as well as the cause of deaths in gynecological cancers.Unlike breast cancer, many women die of ovarian cancer because there is no obvious symptom and no screening test in early stages.Nowadays, only a limited number of tumor markers for ovarian cancer has been cleared by U.S.Food and Drug Administration ( FDA) .In general, tumor marker applications range from diagnosis and curative effect monitoring to predicting prognosis.The article will review the currently available serum markers for ovarian cancer and their clinical application.